The SLICC criteria are validated criteria for making the diagnosis of lupus.
In 2012, the Systemic Lupus International Collaborating Clinics (SLICC) proposed revised classification criteria were released in an effort to improve upon the 1997 American College of Rheumatology (ACR) classification criteria.
Some advantges of SLICC over ACR criteria include:
SLICC criteria requires either that a patient satisfy at least 4 of 17 criteria, including at least 1 of the 11 clinical criteria and one of the six immunologic criteria, or that the patient has biopsy-proven nephritis compatible with SLE in the presence of antinuclear antibodies (ANA) or anti-double-stranded DNA (dsDNA) antibodies.
The SLICC criteria have been validated, and found to have greater sensitivity but lower specificity than the 1997 ACR classification criteria (sensitivity of 97 versus 83 percent and specificity of 84 versus 96 percent, respectively).
Despite the increased sensitivity compared with the ACR criteria, it should be noted that the SLICC criteria might delay the diagnosis of SLE in some patients, and some patients might not be classified at all.
Petri M, Orbai AM, Alarcón GS, et al.
Pons-Estel GJ, Wojdyla D, McGwin G Jr et al.
Lupus malar rash (do not count if malar discoid)
Bullous lupus
Toxic epidermal necrolysis variant of SLE
Maculopapular lupus rash
Photosensitive lupus rash (in the absence of dermatomyositis)
or Subacute cutaneous lupus (nonindurated psoriaform and/or annular polycyclic lesions that resolve without scarring, although occasionally with postinflammatory dyspigmentation or telangiectasias)
In 2012, the Systemic Lupus International Collaborating Clinics (SLICC) proposed revised classification criteria were released in an effort to improve upon the 1997 American College of Rheumatology (ACR) classification criteria.
Some advantges of SLICC over ACR criteria include:
SLICC criteria requires either that a patient satisfy at least 4 of 17 criteria, including at least 1 of the 11 clinical criteria and one of the six immunologic criteria, or that the patient has biopsy-proven nephritis compatible with SLE in the presence of antinuclear antibodies (ANA) or anti-double-stranded DNA (dsDNA) antibodies.
The SLICC criteria have been validated, and found to have greater sensitivity but lower specificity than the 1997 ACR classification criteria (sensitivity of 97 versus 83 percent and specificity of 84 versus 96 percent, respectively).
Despite the increased sensitivity compared with the ACR criteria, it should be noted that the SLICC criteria might delay the diagnosis of SLE in some patients, and some patients might not be classified at all.
Petri M, Orbai AM, Alarcón GS, et al.
Pons-Estel GJ, Wojdyla D, McGwin G Jr et al.
© 2020 QxMD Software Inc., all rights reserved. No part of this service may be reproduced in any way without express written consent of QxMD. This information should not be used for the diagnosis or treatment of any health problem or disease. This information is not intended to replace clinical judgment or guide individual patient care in any manner. Click here for full notice and disclaimer.
